Biofrontera AG
0DOL.L
Get informed when a big investor buys or sells
+ FollowMarket Cap$17.62M
Close$
$1.70
41.2% downside
Current Fair Value
41.2% downsideOvervalued by 41.2% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $17.62 Million |
|---|---|
| Enterprise Value | $20.47 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-0.65 |
| Beta | -0.25 |
| Outstanding Shares | 6,076,862 |
Return
| Return on Equity | -106.87% |
|---|---|
| Return on Assets | -26.45% |
| Return on Invested Capital | -50.93% |
Valuation & Multiples
| P/E Ratio | -1.62 |
|---|---|
| PEG | 1.82 |
| Price to Sales | 0.41 |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | 0.44 |
| Enterprise Value to EBIT | -2.97 |
| Enterprise Value to Net Income | -4 |
| Total Debt to Enterprise | 0.37 |
| Debt to Equity | 1.26 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
September 3, 2026
EPS Estimate
$-1.25
Average shareholder expectationRevenue Estimate
$5.57 M
Average shareholder expectationNext Earnings Call
Expected Date
November 19, 2026
EPS Estimate
$-1.10
Average shareholder expectationRevenue Estimate
$6.00 M
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Biofrontera Inc
82 employees
CEO: Hermann Lübbert Biofrontera AG, a biopharmaceutical company, engages in the research, development, and distribution of dermatological products in Germany, Spain, the United Kingdom, rest of Europe, the United States, and internationally. The company off...